کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5628920 | 1580002 | 2017 | 29 صفحه PDF | دانلود رایگان |
- Non-invasive neuromodulation offers therapeutic potential that is now ready for translation into the developing brain.
- Responsible progress relies on adherence to fundamental principles of clinical trial design and execution.
- Perinatal stroke, a focal injury of defined timing in an otherwise healthy brain, is an ideal model of human developmental plasticity in which models of motor organization are well defined.
- The cortical targets identified represent opportunity for neuromodulation to improve motor function in children with hemiparetic cerebral palsy, the evidence for which is rapidly emerging.
Applications of non-invasive brain stimulation including therapeutic neuromodulation are expanding at an alarming rate. Increasingly established scientific principles, including directional modulation of well-informed cortical targets, are advancing clinical trial development. However, high levels of disease burden coupled with zealous enthusiasm may be getting ahead of rational research and evidence. Experience is limited in the developing brain where additional issues must be considered. Properly designed and meticulously executed clinical trials are essential and required to advance and optimize the potential of non-invasive neuromodulation without risking the well-being of children and families. Perinatal stroke causes most hemiplegic cerebral palsy and, as a focal injury of defined timing in an otherwise healthy brain, is an ideal human model of developmental plasticity. Advanced models of how the motor systems of young brains develop following early stroke are affording novel windows of opportunity for neuromodulation clinical trials, possibly directing neuroplasticity toward better outcomes. Reviewing the principles of clinical trial design relevant to neuromodulation and using perinatal stroke as a model, this article reviews the current and future issues of advancing such trials in children.
Journal: European Journal of Paediatric Neurology - Volume 21, Issue 1, January 2017, Pages 75-103